Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Should cost effectiveness analyses for NICE always consider future unrelated medical costs?

× No keyword cloud information.

8 in total

1. Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients.

Authors: Michelle Tew; Philip Clarke; Karin Thursky; Kim Dalziel
Journal: Pharmacoeconomics Date: 2019-07 Impact factor: 4.981

2. Future Offspring Costs in Economic Evaluation.

Authors: Evelyn Verbeke; Jeroen Luyten
Journal: Pharmacoeconomics Date: 2021-10-29 Impact factor: 4.981

3. Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease.

Authors: James Lomas; Miqdad Asaria; Laura Bojke; Chris P Gale; Gerry Richardson; Simon Walker
Journal: Pharmacoecon Open Date: 2018-12

4. Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia.

Authors: Mark Bounthavong; Javed Butler; Chantal M Dolan; Jeffrey D Dunn; Kathryn A Fisher; Nina Oestreicher; Bertram Pitt; Paul J Hauptman; David L Veenstra
Journal: Pharmacoeconomics Date: 2018-12 Impact factor: 4.981

5. Health system costs for individual and comorbid noncommunicable diseases: An analysis of publicly funded health events from New Zealand.

Authors: Tony Blakely; Giorgi Kvizhinadze; June Atkinson; Joseph Dieleman; Philip Clarke
Journal: PLoS Med Date: 2019-01-08 Impact factor: 11.069

Should cost effectiveness analyses for NICE always consider future unrelated medical costs?

1. Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients.

2. Future Offspring Costs in Economic Evaluation.

3. Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease.

4. Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia.

5. Health system costs for individual and comorbid noncommunicable diseases: An analysis of publicly funded health events from New Zealand.

6. Future Costs in Cost-Effectiveness Analyses: Past, Present, Future.

Review 7. Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature.

8. The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS.